Gilead's Viread approved in US for chronic hepatitis B
This article was originally published in Scrip
Executive Summary
Gilead Sciences' oral anti-HIV drug Viread (tenofovir disoproxil fumarate) has been approved for the treatment of chronic hepatitis B in adults by the USFDA.